Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the impact of adjunctive cilostazol versus high maintenance-dose clopidogrel on platelet inhibition in carriers and non-carriers of the loss-of-function CYP2C19 mutant allele.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gyeongsang National University Hospital
• Treatments: Cilostazol; Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Significant coronary artery stenosis (>70% by visual estimate)

• Elective coronary stent implantation

Exclusion Criteria:

• Acute myocardial infarction

• Active bleeding and bleeding diatheses

• Hemodynamic instability

• Oral anticoagulation therapy with warfarin

• Use of peri-procedural glycoprotein IIb/IIIa inhibitors

• Contraindication to antiplatelet therapy

• Left ventricular ejection fraction < 30%

• Leukocyte count < 3,000/mm3, platelet count < 100,000/mm3, AST or ALT ≥ 3 times upper normal

• Serum creatinine level ≥ 3 mg/dL

• Stroke within 3 months

• Noncardiac disease with a life expectancy < 1 year

• Inability to follow the protocol